Abstracts

EARLY ANTIRETROVIRAL THERAPY IN NEONATES AND MATURATION OF THE GUT MICROBIOME

In the pre antiretroviral therapy (ART) era, breastfeeding has been associated with improved survival outcomes among infants with perinatally-acquired HIV infection. Breastfeeding is known to support optimal establishment of a healthy gut microbiome. Here we investigated whether breastfeeding and early ART mitigate harmful influences of intrauterine HIV infection on the developing infant microbiome. At one…

THE SUBPHENOTYPES OF EARLY-TREATED CHILDREN LIVING WITH HIV-1

Subphenotypes have been identified in several heterogeneous diseases. Having a specific subphenotype often has therapeutic implications or impacts disease progression. In this study, we aimed to assess if children with HIV may show subphenotypes according to clinical, virological and immunological features. We collected data from 40 HIV+ children included in a cross-sectional multicentric study (CARMA…

SEVERE IMMUNE SUPPRESSION AND RETENTION AMONG INFANTS IN SOUTH AFRICA

Following rapid improvements in HIV programs, children are now starting antiretroviral therapy (ART) younger and healthier. Among infants, sustained retention and adherence to ART is especially challenging, and it is possible that severe immune suppression (SIS) will be increasingly seen among those on ART. We aimed to describe SIS and retention among infants on ART.…

HIGH PREVALENCE OF HIV DRUG RESISTANCE AMONG NEWLY DIAGNOSED CHILDREN 0-18 MONTHS

Exposure to maternal antiretroviral treatment (ART) and infant postnatal antiretroviral (ARV) prophylaxis risks emergence of pre-treatment drug resistance (DR) in children who get breakthrough HIV infection through mother to child transmission. We estimated the national prevalence of pre-treatment HIV DR among newly diagnosed HIV-infected infants 0 to 18 months in Kenya. A nationally representative cross-sectional…

LIVING: 48-WEEK DATA ON LPV/r PELLETS IN 990 CHILDREN IN RESOURCE-LIMITED SETTINGS

LPV/r-based regimens remain an important treatment for children living with HIV (CLHIV), with established safety and efficacy. LPV/r pellets are an alcohol-free, heat stable improvement on LPV/r liquid for CLHIV who cannot swallow tablets. Treatment outcome data from large cohorts of CLHIV in resource-poor settings are limited. LIVING (NCT02346487) addresses this data gap across pediatric…